If you have the means to help, we’ve compiled verified pages linked to families that have setup GoFundMe sites to help with ...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade 1-3   HS often emerges around puberty, underscoring importance of ...
UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...